Autonomic focus Target autonomic disorder specialists and headache clinics with strategic outreach highlighting ATI’s Pulsante Microstimulator as a CE-marked therapy for cluster headaches and its ongoing US IDE study, positioning ATI as an innovator in neurostimulation for severe headaches.

Clinical expansion Leverage ATI’s CE approval in Europe and ongoing US IDE study to propose cross-border or US-europe collaborative opportunities, including clinical partnerships, investigator-initiated trials, and access to European sites for expanded data generation.

Financial capacity Present ATI’s funding breadth to prospects as a validation of growth potential and capability to scale commercialization efforts, enabling discussions around co-investment, pilot programs, or phased market entry strategies.

Smaller team agility Highlight ATI’s lean team size as an opportunity to offer scalable, turnkey support solutions for hospital adoption, including training programs, remote monitoring, and streamlined clinical workflows that align with a compact organizational structure.

Strategic partnerships Position ATI alongside mid-to-large players in neurostimulation and pain management as a potential partner for distribution, integration with existing neurostimulation portfolios, or collaborative R&D to accelerate pipeline and market reach.